Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Abstract Introduction Nivolumab is approved for the treatment of advanced non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study evaluated long-term outcomes, safety and feasibility of immunotherapy rechallenge in French patients with previ...

詳細記述

書誌詳細

主要な著者:	Benoît Godbert, Elisa Gobbini, Yaacoub Khalife, Chantal Decroisette, Florence Brellier, Hervé Lena, Anne Fleuriet, Maeva Zysman, Thomas Egenod, Nicolas Girard
フォーマット:	Artigo
言語:	Inglês
出版事項:	Adis, Springer Healthcare 2026-05-01
シリーズ:	Oncology and Therapy
主題:	Immune checkpoint inhibitors Immunotherapy rechallenge Nivolumab Non-small cell lung cancer Real-world evidence
オンライン･アクセス:	https://doi.org/10.1007/s40487-026-00437-8
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!